|
|
影响胆囊癌的炎症指标及治疗
|
Abstract:
胆囊癌(GBC)是一种高度恶性的肿瘤，占胆道恶性肿瘤的80%~95%。胆囊癌在所有胆囊切除术中的发生率为0.2%~3%，在所有腹腔镜胆囊切除术中的发生率为0.09%~2%。手术切除是胆囊癌唯一的根治办法。手术应根据TNM分期决定手术切术范围，充分的术前评估对于提高根治率改善病人预后极为重要。胆囊癌的预后较差，总的5年生存率不到5%。在疾病早期，如果进行分期调整治疗，5年生存率可达75%。其发病率较低，症状不清，导致大多数患者在诊断时表现为晚期，导致其预后差。胆囊癌的全身化疗方案与胆管癌相似，包括吉西他滨和顺铂一线化疗，FOLFOX第二线化疗方案。目前正在进行的第三阶段临床试验可能会改变这种癌症的系统治疗模式。
Gallbladder carcinoma (GBC) is a highly malignant tumor, accounting for 80%~95% of biliary ma-lignancies. The incidence of gallbladder cancer is 0.2%~3% in all cholecystectomies and 0.09%~2% in all laparoscopic cholecystectomies. Surgical excision is the only cure for gallbladder cancer. The scope of surgical resection should be determined according to TNM staging. Adequate preoperative evaluation is very important to improve the radical rate and prognosis of patients. Gallbladder can-cer has a poor prognosis, with an overall 5-year survival rate of less than 5%. In the early stages of the disease, with stage-adjusted treatment, the 5-year survival rate is 75%. Its low incidence and unclear symptoms result in the late stage of diagnosis in most patients, resulting in a poor progno-sis. The systemic chemotherapy regimen for gallbladder cancer is similar to that for cholangiocar-cinoma, including first-line chemotherapy with gemcitabine and cisplatin and second-line chemo-therapy with FOLFOX. A Phase 3 clinical trial currently underway could change the systematic treatment paradigm for this cancer.
| [1] | Wang, Z., Liu, H., Dou, M., Du, X., Hu, J., Su, N., Wang, Y., Zhang, R. and Li, C. (2017) The Quality Changes in Fresh Frozen Plasma of the Blood Donors at High Altitude. PLOS ONE, 12, e0176390.
https://doi.org/10.1371/journal.pone.0176390 |
| [2] | Frisancho, A.R. (2013) Developmental Functional Adaptation to High Altitude: Review. American Journal of Human Biology, 25, 151-168. https://doi.org/10.1002/ajhb.22367 |
| [3] | Weitz, C.A. and Garruto, R.M. (2004) Growth of Han Migrants at High Altitude in Central Asia. American Journal of Human Biology, 16, 405-419. https://doi.org/10.1002/ajhb.20042 |
| [4] | 张彦博, 汪源, 刘学良, 等. 人与高原[M]. 西宁: 青海人民出版社, 1996: 347. |
| [5] | 张永海, 郁慕仪, 向兴利, 毛辉青. 不同海拔高度正常成人脾脏大小CT观测[J]. 高原医学杂志, 1999, 9(1): 23-27. |
| [6] | Donohue, J.H., Na-gorney, D.M., Grant, C.S., Tsushima, K., Ilstrup, D.M. and Adson, M.A. (1990) Carcinoma of the Gallbladder: Does Radical Resection Improve Outcome. Archives of Surgery, 125, 237-241.
https://doi.org/10.1001/archsurg.1990.01410140115019 |
| [7] | Gukovsky, I., Li, N., Todoric, J., Gukovskaya, A. and Karin, M. (2013) Inflammation, Autophagy, and Obesity: Common Features in the Pathogenesis of Pancreatitis and Pancreatic Cancer. Gastroenterology, 144, 1199-1209.
https://doi.org/10.1053/j.gastro.2013.02.007 |
| [8] | Yang, L. and Karin, M. (2014) Roles of Tumor Suppressors in Regulating Tumor-Associated Inflammation. Cell Death & Differentiation, 21, 1677-1686. https://doi.org/10.1038/cdd.2014.131 |
| [9] | Roxburgh, C.S. and McMillan, D.C. (2010) Role of Systemic Inflam-matory Response in Predicting Survival in Patients with Primary Operable Cancer. Future Oncology, 6, 149-163. https://doi.org/10.2217/fon.09.136 |
| [10] | Grivennikov, S.I., Greten, F.R and Karin, M. (2010) Immunity, Inflamma-tion, and Cancer. Cell, 140, 883-899.
https://doi.org/10.1016/j.cell.2010.01.025 |
| [11] | Mady, M., Prasai, K., Tella, S.H., Yadav, S., Hallemeier, C.L., Rakshit, S., et al. (2020) Neutrophil to Lymphocyte Ratio as a Prognostic Marker in Metastatic Gallbladder Cancer. HPB, 22, 1490-1495.
https://doi.org/10.1016/j.hpb.2020.02.002 |
| [12] | Jansson, H., Cornillet, M., Bj？rkstr？m, N.K., Sturesson, C. and Sparrelid, E. (2020) Prognostic Value of Preoperative Inflflammatory Markers in Resectable Biliary Tract Can-cer—Validation and Comparison of the Glasgow Prognostic Score and Modifified Glasgow Prognostic Score in a West-ern Cohort. European Journal of Surgical Oncology, 46, 804-810. https://doi.org/10.1016/j.ejso.2019.12.008 |
| [13] | Saqib, R., Pathak, S., Smart, N., Nunes, Q., Rees, J., Finch Jones, M. and Poston, G. (2018) Prognostic Signifificance of Pre-Operative Inflflammatory Markers in Resected Gallbladder Cancer: A Systematic Review. ANZ Journal of Surgery, 88, 554-559. https://doi.org/10.1111/ans.14300 |
| [14] | Biswas, T., Kang, K.H., Gawdi, R., et al. (2020) Using the Systemic Im-mune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Environmental Research and Public Health, 17, 7995-8008.
https://doi.org/10.3390/ijerph17217995 |
| [15] | Jomrich, G., Gruber, E.S., Winkler, D., et al. (2020) Systemic Im-mune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. Journal of Gastrointestinal Surgery, 24, 610-618.
https://doi.org/10.1007/s11605-019-04187-z |
| [16] | Yatabe, S., Eto, K., Haruki, K., et al. (2020) Signification of Systemic Immune-Inflammation Index for Prediction of Prognosis after Resecting in Patients with Colorectal Cancer. In-ternational Journal of Colorectal Disease, 35, 1549-1555.
https://doi.org/10.1007/s00384-020-03615-w |
| [17] | Ozbek, E., Besiroglu, H., Ozer, K., Horsanali, M.O. and Gorgel, S.N. (2020) Systemic Immune Inflammation Index is a Promising Non-Invasive Marker for the Prognosis of the Patients with Localized Renal Cell Carcinoma. International Urology and Nephrology, 52, 1455-1463. https://doi.org/10.1007/s11255-020-02440-y |
| [18] | Zhang, X., Niu, Y., Wang, X., et al. (2018) Mean Platelet Vol-ume and Platelet Distribution Width Are Associated with Gallbladder Cance. Asian Pacific Journal of Cancer Prevention, 19, 351-355. |
| [19] | Wang, R.-T., Zhang, L.-Q., Mu, Y.-P., et al. (2015) Prognostic Significance of Preoperative Platelet Count in Patients with Gallbladder Cancer. World Journal of Gastroenterology, 21, 5303-5310.
https://doi.org/10.3748/wjg.v21.i17.5303 |
| [20] | Javle, M., Churi, C., Kang, H.C., et al. (2015) HER2/Neu-Directed Therapy for Biliary Tract Cancer. Journal of Hematology & Oncology, 8, Article No. 58. https://doi.org/10.1186/s13045-015-0155-z |
| [21] | Lowery, M.A., Ptashkin, R., Jordan, E., et al. (2018) Comprehen-sive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clini-cal Cancer Research, 24, 4154-4161.
https://doi.org/10.1158/1078-0432.CCR-18-0078 |
| [22] | 董家鸿, 王剑明, 曾建平. 胆囊癌诊断和治疗指南(2015版) [J]. 临床肝胆病杂志, 2016, 32(3): 411-419. |
| [23] | Sachs, T.E., Akintorin, O. and Tseng, J. (2018) How Should Gallbladder Cancer Be Managed? Advances in Surgery, 52, 89-100. https://doi.org/10.1016/j.yasu.2018.04.003 |
| [24] | Shirobe, T. and Maruyama, S. (2015) Laparoscopic Radical Chol-ecystectomy with Lymph Node Dissection for Gallbladder Carcinoma. Surgical Endoscopy, 29, 2244-2250. https://doi.org/10.1007/s00464-014-3932-9 |
| [25] | Yoon, Y.-S., Han, H.-S., Cho, J.-Y., et al. (2015) Is Laparoscopy Contraindicated for Gallbladder Cancer? A 10-Year Prospective Cohort Study. Journal of the American College of Sur-geons, 221, 847-853.
https://doi.org/10.1016/j.jamcollsurg.2015.07.010 |
| [26] | Valle, J., Wasan, H., Palmer, D.H., et al. (2010) Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New England Journal of Medicine, 362, 1273-1281. https://doi.org/10.1056/NEJMoa0908721 |
| [27] | Chen, C., Geng, Z., Shen, H., et al. (2016) Long-Term Outcomes and Prognostic Factors in Advanced Gallbladder Cancer: Focus on the Advanced T Stage. PLOS ONE, 11, e0166361. https://doi.org/10.1371/journal.pone.0166361 |
| [28] | Zhou, Y., Zhang, Z., Wu, L. and Li, B. (2016) A Systematic Review of Safety and Efficacy of Hepatopancreatoduodenectomy for Biliary and Gallbladder Cancers. HPB, 18, 1-6. https://doi.org/10.1016/j.hpb.2015.07.008 |
| [29] | Goetze, T.O. (2015) Gallbladder Carcinoma: Prognostic Factors and Therapeutic Options. World Journal of Gastroenterology, 21, 12211-12217. https://doi.org/10.3748/wjg.v21.i43.12211 |
| [30] | 刘杰, 张成武. 腹腔镜技术在胆道恶性肿瘤外科治疗中的应用[J]. 肝胆胰外科杂志, 2018, 30(2): 89-93. |
| [31] | Sheinfeld, W. (1947) Cholecystectomy and Partial Hepatectomy for Carcinoma of the Gall Bladder with Local Liver Extension. Surgery, 22, 48-58. |
| [32] | Glenn, F. and Hays, D.M. (1953) Carcinoma of the Extrahepatic Biliary Tract. Surgical Clinics of North America, 33, 479-492. https://doi.org/10.1016/S0039-6109(16)33892-0 |
| [33] | Glenn, F. and Hays, D.M. (1954) The Scope of Radical Surgery in the Treatment of Malignant Tumors of the Extrahepatic Biliary Tract. Surgery, Gynecology and Obstetrics, 99, 529-541. |
| [34] | Pack, G.T., Miller, T.R. and Brasfield, R.D. (1955) Total Right Hepatic Labectomy for Cancer of the Gallbladder: Report of Three Cases. Annals of Surgery, 142, 6-16. https://doi.org/10.1097/00000658-195507000-00002 |
| [35] | Fahim, R.B., McDonald, J.R., Richards, J.C. and Ferris, D.O. (1962) Carcinoma of the Gallbladder: A Study of Its Modes of Spread. Annals of Surgery, 156, 114-124. https://doi.org/10.1097/00000658-196207000-00021 |
| [36] | Benson 3rd, A.B., Abrams, T.A., Ben-Josef, E., Bloom-ston, P.M., Botha, J.F., Clary, B.M., Covey, A., Curley, S.A., D’Angelica, M.I., Davila, R., Ensminger, W.D., Gibbs, J.F., Laheru, D., Malafa, M.P., Marrero, J., Meranze, S.G., Mulvihill, S.J., Park, J.O., Posey, J.A., Sachdev, J., Salem, R., Sigurdson, E.R., Sofocleous, C., Vauthey, J.N., Venook, A.P., Goff, L.W., Yen, Y. and Zhu, A.X. (2009) NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Journal of the National Comprehensive Cancer Net-work, 7, 350-391.
https://doi.org/10.6004/jnccn.2009.0027 |
| [37] | Javle, M., Rashid, A., Churi, C., et al. (2014) Molecular Characteri-zation of Gallbladder Cancer Using Somatic Mutation Profiling. Human Pathology, 45, 701-708. https://doi.org/10.1016/j.humpath.2013.11.001 |
| [38] | Shroff, R.T., Javle, M.M., Xiao, L., et al. (2019) Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA On-cology, 5, 824-830.
https://doi.org/10.1001/jamaoncol.2019.0270 |
| [39] | Phelip, J.-M., Edeline, J., Blanc, J.F., et al. (2019) Modified FOLFIRINOX versus CisGem First-Line Chemotherapy for Locally Advanced Non Resectable or Metastatic Biliary Tract Cancer (AMEBICA)-PRODIGE 38: Study Protocol for a Randomized Controlled Multicenter Phase II/III Study. Digestive and Liver Disease, 51, 318-320.
https://doi.org/10.1016/j.dld.2018.11.018 |
| [40] | Lamarca, A., Hubner, R.A., David Ryder, W. and Valle, J.W. (2014) Second-Line Chemotherapy in Advanced Biliary Cancer: A Systematic Review. Annals of Oncology, 25, 2328-2338. https://doi.org/10.1093/annonc/mdu162 |
| [41] | Goff, L.W., Lowery, M.A., Jordan, E., et al. (2016) Second-Line Chemotherapy (CTx) Outcomes in Advanced Biliary Cancers (ABC): A Retrospective Multicenter Analysis. Journal of Clinical Oncology, 34, e15636.
https://doi.org/10.1200/JCO.2016.34.15_suppl.e15636 |
| [42] | Lamarca, A., Palmer, D.H., Wasan, H.S., et al. (2019) A Randomised Phase III, Multi-Centre, Open-Label Study of Active Symptom Control (ASC) Alone or ASC with Ox-aliplatin / 5-FU Chemotherapy (ASC+mFOLFOX) for Patients (pts) with Locally Advanced/Metastatic Biliary Tract Cancers (ABC) Previously-Treated with Cisplatin/Gemcitabine (CisGem) Chemotherapy. Journal of Clinical Oncology, 37, e4003.
https://doi.org/10.1200/JCO.2019.37.15_suppl.4003 |
| [43] | Lamarca, A., Barriuso, J., McNamara, M.G. and Valle, J.W. (2018) Biliary Tract Cancer: State of the Art and Potential Role of DNA Damage Repair. Cancer Treatment Reviews, 70, 168-177. https://doi.org/10.1016/j.ctrv.2018.09.002 |
| [44] | Jain, A., Kwong, L.N. and Javle, M. (2016) Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Current Treatment Options in Oncology, 17, Ar-ticle No. 58. https://doi.org/10.1007/s11864-016-0432-2 |
| [45] | Ueno, M., Chung, H.C., Nagrial, A., et al. (2018) Pembrolizumab for Advanced Biliary Adenocarcinoma: Results from the Multicohort, Phase II KEYNOTE-158 Study. Annals of Oncology, 29, VIII210.
https://doi.org/10.1093/annonc/mdy282.009 |
